LYN-005
- Generic Name
- LYN-005
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Phase 3
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Lyndra Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05779241
- Locations
- 🇺🇸
CenExel CNS, Garden Grove, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Uptown Research Institute, Chicago, Illinois, United States
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Lyndra Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04567524
- Locations
- 🇺🇸
Community Clinical Research, Inc, Austin, Texas, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸Collaborative Neuroscience Research, LLC, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath